Press Releases Latest Jul 10, 2024 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 Press Releases Year None202420232022202120202019201820172016201520142013 Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023 May 09, 2023 Theratechnologies Reports on its Annual Meeting of Shareholders May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies Apr 12, 2023 Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023 Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update First page « Previous page ‹ … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page › Last page » Displaying 51 - 60 of 365
Jul 10, 2024 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Jun 29, 2023 Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
Jun 22, 2023 Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Jun 12, 2023 Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update